File(s) not publicly available
The Impact of Posttraumatic Stress Disorder on Pharmacologic Intervention Outcomes for Adults With Bipolar Disorder: A Systematic Review
journal contributionposted on 2023-02-10, 01:49 authored by Samantha RussellSamantha Russell, AL Wrobel, David SkvarcDavid Skvarc, Bianca KavanaghBianca Kavanagh, Melanie AshtonMelanie Ashton, Olivia DeanOlivia Dean, Michael BerkMichael Berk, Alyna TurnerAlyna Turner
Abstract Background The prevalence of posttraumatic stress disorder (PTSD) co-occurring in people with bipolar disorder (BD) is high. People with BD and PTSD may experience different outcomes and quality of life after pharmacologic treatment than those with BD alone. This review systematically explores the impact of PTSD on pharmacologic treatment outcomes for adults with BD. Methods We conducted a systematic search up to November 25, 2021, using MEDLINE Complete, Embase, American Psychological Association PsycInfo, and the Cochrane Central Register of Controlled Trials to identify randomized and nonrandomized studies of pharmacologic interventions for adults with BD that assessed for comorbid PTSD. We used the Newcastle-Ottawa Scale and Cochrane Risk of Bias tool to assess the risk of bias. Results The search identified 5093 articles, and we reviewed 62 full-text articles. Two articles met inclusion criteria (N = 438). One article was an observational study, and the other was a randomized comparative effectiveness trial. The observational study examined lithium response rates and found higher response rates in BD alone compared with BD plus PTSD over 4 years. The randomized trial reported more severe symptoms in the BD plus PTSD group than in those with BD alone following 6 months of quetiapine treatment. There was no significant difference in the lithium treatment group at follow-up. Conclusions Comorbid PTSD may affect quetiapine and lithium treatment response in those with BD. Because of the high risk of bias and low quality of evidence, however, these results are preliminary. Specific studies exploring comorbid BD and PTSD are required to inform pharmacotherapy selection and guidelines appropriately. (International Prospective Register of Systematic Reviews ID: CRD42020182540).
JournalThe international journal of neuropsychopharmacology
Publication classificationC1 Refereed article in a scholarly journal
PublisherOXFORD UNIV PRESS
Science & TechnologyLife Sciences & BiomedicineClinical NeurologyNeurosciencesPharmacology & PharmacyPsychiatryNeurosciences & NeurologyCLINICAL-PRACTICE GUIDELINESNEW-ZEALAND COLLEGEANXIETY DISORDERSSUICIDAL IDEATIONPREVALENCECOMORBIDITYTRAUMASAMPLEPOPULATIONREDUCTIONAdultHumansStress Disorders, Post-TraumaticCognitive Behavioral TherapyBipolar DisorderQuetiapine FumarateQuality of LifeSystematic Reviews as TopicLithium CompoundsObservational Studies as TopicClinical ResearchSerious Mental IllnessComparative Effectiveness ResearchClinical Trials and Supportive ActivitiesPost-Traumatic Stress Disorder (PTSD)Mental HealthBrain Disorders6.6 Psychological and behavioural7 Management of diseases and conditions6.1 Pharmaceuticals7.1 Individual care needs6 Evaluation of treatments and therapeutic interventionsMental health3 Good Health and Well BeingMedical and Health SciencesPsychology and Cognitive Sciences